STRASBOURG, France,
Dec. 10, 2020 /CNW/ - Nanalysis
Scientific Corp. (Nanalysis), (TSXV: NSCI) (OTCQX: NSCIF) (FRA:
1N1), through its subsidiary RS2D S.A.S. (RS2D), is pleased to
announce that it has won a C$1.2M
non-repayable grant to further leverage its proprietary Nuclear
Magnetic Resonance Imaging (MRI) technology for smart NextGen
clinical MRI systems. This product, based on the
Cameleon4TM Original Equipment Manufacturer (OEM)
product, will advance these devices an additional step towards the
personalized medicine of the future.
Rémy Schimpf, Senior VP Sales states "We are very pleased to win
this competitive project, which is consistent with our strategy to
leverage our Nuclear Magnetic Resonance (NMR) spectroscopy
technology for MRI applications, which we offer through OEM
partnerships. When I founded RS2D 15 years ago, I had a vision to
build a family of products in NMR and MRI that use a common
technology platform. We are succeeding at this objective. I am
extremely proud that our application was selected together with 60
other successful projects out of 902 submissions, by experts at the
European Commission (EC), receiving a perfect score of 5 out of 5.
The EC evaluators stated in writing that our project has a unique
'Clarity of the radical vision of a science-enabled technology and
its differentiation from current paradigms'.
This project combines our Cameleon4TM technology,
used in our benchtop and high-field NMR products, with our NextGen
software, in partnership with leaders in personalized medicine and
high sensitivity MRI technology such as Haute Ecole Specialisée de
Suisse Occidental in Basel,
Switzerland. MRI is a very powerful and widely used
diagnostic technique, but it has a known weakness: Sensitivity. The
main objective of this project is to demonstrate that tremendous
sensitivity gains can be achieved using magnetic resonance to
activate gamma emissions. Combined with Artificial
Intelligence software techniques, this can lead to life-saving
medical solutions in the near future."
Sean Krakiwsky, founder and CEO
of Nanalysis added, "Working with such an impressive consortium of
organizations is a testament to our position as a global innovator
in NextGen NMR and MRI technology. We are developing safe and smart
solutions for the personalized medicine of tomorrow. Projects
such as this, along with our Alternatives to Gadolinium MRI project
and others, will lead us to exciting product opportunities which we
will launch with partners. We are pursuing this strategy, while
maintaining profitability in our MRI business unit, which includes
installation and maintenance of full systems, so that we remain
connected to the needs of MRI users, as we develop NextGen
technologies. Our MRI and NMR teams work very closely together to
maximize overlap and more importantly to identify unique patent
protected technology commonalities at the math and physics level. I
am incredibly proud of our team in Strasbourg, which is leading this area of
innovation for our company."
The following organizations are part of the successful project
entitled "Gamma-MRI: The future of molecular imaging":
Haute Ecole Specialisée de Suisse Occidental, Switzerland
University de Geneve,
Switzerland
Universidad Complutense de Madrid,
Spain
RS2D SAS, France
European Organization for Nuclear Research, Switzerland
Katholieke Universiteit Leuven, Belgium
Tecnologias Avanzadas Iinspiralta SL, Spain
Partners are in the process of signing the official Consortium
Agreement, which has an internal deadline of December 15, 2020, after which the EC will ratify
the project.
About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA:
1N1)
Nanalysis trades on the TSX Venture Exchange (TSXV) in
Canada with ticker symbol 'NSCI'
and Over the Counter (OTC) in the United
States under the ticker symbol 'NSCIF'.
Nanalysis business is what we term "MRI for industry": It
develops and manufactures portable NMR spectrometers or analyzers
for laboratory and industrial markets. The NMReady60™ was the first
fully featured portable NMR spectrometer in a single compact
enclosure requiring no liquid helium or any other cryogens, and the
company continues to develop new products and has a strong
innovation pipeline. Nanalysis began taking orders for the 100MHz
device in early 2020. The Company's new device will be the most
powerful non-cryogen, permanent magnet compact NMR device ever
brought to market. Nanalysis devices are used by chemical
professionals in many industries (oil and gas, chemical, mining,
pharma, biotech, flavor and fragrances, agrochemicals, and more) as
well as numerous government and university research labs around the
world. The company continues to exploit new global market
opportunities both independently and with partners.
In March 2020, the Company
acquired all outstanding shares of RS2D, a complementary technology
company based in Strasbourg France
that specializes in the development of cutting-edge MR
electronics. Based on a single electronic board, RS2D has
developed MR product lines in high-field (HF) NMR and magnetic
resonance imaging (MRI) that can further advance Nanalysis'
existing product line, while the new products to round out the
Company's magnetic resonance technology portfolio.
Notice regarding Forward Looking Statements and Legal
Disclaimer
This news release contains certain "forward-looking statements"
within the meaning of such statements under applicable securities
law. Forward-looking statements are frequently characterized by
words such as "anticipates", "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed", "positioned" and other similar
words, or statements that certain events or conditions "may" or
"will" occur. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
SOURCE Nanalysis Scientific Corp.